Andrew Witty is stepping down for "personal reasons" while the Minnesota-based insurer suspends its full-year financial ...

Lockheed Martin lays off 64 Mass. clean energy workers Lockheed Martin lays off 64 Mass. clean energy workers © 2025 American ...

The new acquisition from Boston Pharmaceuticals adds to a wave of dealmaking undertaken by GSK to build its liver disease ...

British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a ...

GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm ...

GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, a phase III-ready investigational specialty medicine.

Global biopharmaceutical leader GSK PLC has entered into a definitive agreement to acquire efimosfermin, a promising ...

UnitedHealth Group Inc. on May 13 issued an update with two items of notable news, saying that its medical costs are likely ...

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.

GSK plans to purchase an experimental drug for the liver disease MASH from Boston Pharmaceuticals for $1.2 billion upfront.

In recent years, the U.K.-listed pharma giant has called increasingly on U.S. law firms for its transactional work.

GlaxoSmithKline (GSK) has announced the repurchase of 783,700 of its ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction is part ...